Pathak Ashish, Mårtensson Andreas, Gawariker Sudhir, Mandliya Jagdish, Sharma Ashish, Diwan Vishal, Ursing Johan
Malaria Research, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Malar J. 2014 May 15;13:182. doi: 10.1186/1475-2875-13-182.
Since 2011, artesunate + sulphadoxine-pyrimethamine (ASP), instead of chloroquine, has been recommended for treatment of uncomplicated malaria in India. In Ujjain, central India, with an annual parasite index <0.1, the prevalence of drug-resistant Plasmodium falciparum is unknown. In other parts of India chloroquine and sulphadoxine-pyrimethamine-resistant P. falciparum is prevalent. The aim of this study was to determine the prevalence of anti-malarial drug resistance-associated genetic polymorphisms in P. falciparum collected in Ujjain in 2009 and 2010, prior to the introduction of ASP.
Blood samples from 87 patients with P. falciparum mono-infection verified by microscopy were collected on filter-paper at all nine major pathology laboratories in Ujjain city. Codons Pfcrt 72-76, pfmdr1 1034-1246, pfdhfr 16-185, pfdhps 436-632 and pfnhe1 ms4760 haplotypes were identified by sequencing. Pfcrt K76T and pfmdr1 N86Y were identified by restriction fragment length polymorphism, and pfmdr1 gene copy number by real-time PCR.
Sulphadoxine-pyrimethamine resistance-associated pfdhfr 108 N and 59R alleles were found in 75/78 (96%) and 70/78 (90%) samples, respectively, and pfdhps 437G was found in 7/77 (9%) samples. Double mutant pfdhfr 59R + 108 N were found in 62/76 (82%) samples. Triple mutant pfdhfr 59R + 108 N and pfdhps 437G were found in 6/76 (8%) samples. Chloroquine-resistance-associated pfcrt 76 T was found in 82/87 (94%). The pfcrt 72-76 haplotypes found were: 80/84 (95%) SVMNT, 3/84 (4%) CVMNK and 1/84 (1%) CVMNT. Pfmdr1 N86 and 86Y were identified in 70/83 (84%) and 13/83 (16%) samples, respectively. Pfmdr1 S1034 + N1042 + D1246 were identified together in 70/72 (97%) of successfully sequenced samples. One pfmdr1 gene copy was found in 74/75 (99%) successfully amplified samples.
This is the first characterization of key anti-malarial drug resistance-associated genetic markers among P. falciparum collected in Ujjain, Madhya Pradesh, India. The results indicate that the efficacy of standard dose chloroquine at the time of the study was likely to be poor, whereas ASP was likely to be efficacious, supporting the changed drug treatment policy. However, P. falciparum with reduced susceptibility to sulphadoxine-pyrimethamine is highly prevalent, highlighting the need for continuous surveillance of ASP efficacy in the study area.
自2011年起,印度推荐使用青蒿琥酯+磺胺多辛-乙胺嘧啶(ASP)而非氯喹来治疗非复杂性疟疾。在印度中部的乌贾因,年寄生虫指数<0.1,耐氯喹恶性疟原虫的流行情况未知。在印度其他地区,耐氯喹和耐磺胺多辛-乙胺嘧啶的恶性疟原虫很普遍。本研究的目的是确定2009年和2010年在乌贾因采集的、引入ASP之前的恶性疟原虫中与抗疟药耐药性相关的基因多态性的流行情况。
在乌贾因市的所有9个主要病理实验室,从87例经显微镜检查确诊为恶性疟原虫单一感染的患者的血液样本中采集滤纸血样。通过测序鉴定密码子Pfcrt 72-76、pfmdr1 1034-1246、pfdhfr 16-185、pfdhps 436-632和pfnhe1 ms4760单倍型。通过限制性片段长度多态性鉴定Pfcrt K76T和pfmdr1 N86Y,通过实时PCR鉴定pfmdr1基因拷贝数。
在75/78(96%)和70/78(90%)的样本中分别发现了与磺胺多辛-乙胺嘧啶耐药性相关的pfdhfr 108N和59R等位基因,在7/77(9%)的样本中发现了pfdhps 437G。在62/76(82%)的样本中发现了双突变pfdhfr 59R+108N。在6/76(8%)的样本中发现了三突变pfdhfr 59R+108N和pfdhps 437G。在82/87(94%)的样本中发现了与氯喹耐药性相关的pfcrt 76T。发现的pfcrt 72-76单倍型为:80/84(95%)SVMNT、3/84(4%)CVMNK和1/84(1%)CVMNT。在70/83(84%)和13/83(16%)的样本中分别鉴定出pfmdr1 N86和86Y。在70/72(97%)成功测序的样本中共同鉴定出pfmdr1 S1034+N1042+D1246。在74/75(99%)成功扩增的样本中发现一个pfmdr1基因拷贝。
这是对在印度中央邦乌贾因采集的恶性疟原虫中与主要抗疟药耐药性相关的基因标记的首次特征描述。结果表明,研究时标准剂量氯喹的疗效可能较差,而ASP可能有效,这支持了改变后的药物治疗政策。然而,对磺胺多辛-乙胺嘧啶敏感性降低的恶性疟原虫非常普遍,突出了在研究地区持续监测ASP疗效的必要性。